What Neurogen Biomarking does

Neurogen Biomarking is a US-based health technology company operating a direct-to-consumer platform for early detection of Mild Cognitive Impairment and dementia associated with Alzheimer's disease. Founded in January 2025 by Dr. Rany Aburashed and headquartered in Chicago, the company sells an at-home test kit that combines a P-tau217 blood biomarker assay run on Quanterix's ultrasensitive Simoa antibody platform with an AI-driven digital cognitive assessment delivered through Linus Health, with blood collection options spanning concierge phlebotomy and Tasso's FDA-cleared needle-free device. Test results are reviewed by board-certified neurologists accessed via the NeuroX telehealth network, who deliver a personalized brain-health action plan to the consumer.

The platform's underlying technology stack is an integration of licensed best-in-class components rather than a single in-house diagnostic: an exclusive global agreement with Quanterix provides the biomarker chemistry, Linus Health provides the cognitive analytics layer, NeuroX provides AI-augmented neurology consults (with participation in the CMS GUIDE Model), Tasso provides the sampling hardware, and Aranscia provides CLIA-certified lab and HIPAA-compliant workflow support. The scientific advisory committee includes investigators from Harvard, Wake Forest, the University of Pittsburgh, Banner Health, Indiana University, Amsterdam UMC, and Memorial Healthcare, giving the company credible clinical positioning despite a 1-10 person headcount.

Revenue is generated primarily through one-time DTC kit sales priced between roughly $365 and $799, with payment processed via Stripe and a Klarna pay-later option. Go-to-market is multi-modal: a website storefront and content-marketing blog, earned media coverage (including appearances on OZ and The Morning Show), and free community 'Brain Health Day' events co-sponsored with organizations such as the Global Alzheimer's Platform Foundation and Insight Hospital to drive awareness in underserved populations. Operating geographies are listed across the United States, Canada, the United Kingdom, Germany, the Netherlands, Sweden, and Australia, consistent with the pan-regional scope of the Quanterix license.

Name

Neurogen Biomarking

Legal name

Neurogen Biomarking LLC

Website

https://neurogenbiomarking.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

Neurogen Biomarking is a Chicago-based health technology company selling a direct-to-consumer at-home Alzheimer's detection kit that combines Quanterix P-tau217 blood biomarker testing, Linus Health AI cognitive assessments, and NeuroX telehealth neurologist consultations for adults 55+ and at-risk individuals.

Ownership category

akta.pro rank

Headquarters

HQ city

Chicago

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. At-Home Alzheimer's Test Kit Sales: One-time purchase of at-home test kit that includes blood collection, cognitive assessment, neurologist review, and 1-on-1 consultation. The kit provides biomarker testing, digital cognitive assessments, and personalized brain health roadmap. Payment processing through Stripe with Klarna pay-later option available.
2. Telehealth Consultation Services: Initial consultation with board-certified neurologist included with kit purchase. Ongoing care available through continued work with neurologist after initial consultation. Initial consultation included; ongoing care not covered by Neurogen.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Neurogen Biomarking sells a direct-to-consumer at-home Alzheimer's test kit that includes a p-tau217 blood biomarker test (run via Quanterix technology), AI-powered digital cognitive assessments (via Linus Health), telehealth neurologist consultation (via NeuroX), and a personalized brain health action plan. The kit is ordered online, the blood sample is collected at home (phlebotomy or Tasso needle-free), and results are delivered within one week with neurologist-guided next steps.

Product overview

Neurogen Biomarking is a health technology company offering the world's first proactive Memory Health ecosystem for early Alzheimer's disease detection. The platform is a unified system combining multiple integrated modules: an at-home Alzheimer's test kit (the core product), a P-tau217 blood biomarker test using Quanterix ultrasensitive technology, AI-powered digital cognitive assessments (via Linus Health), telehealth neurologist consultations (via NeuroX), a personalized Brain Health Action Plan, and secure lifetime results tracking — all accessible directly by consumers without a doctor's prescription. The ecosystem is designed to detect Alzheimer's risk decades before severe symptoms appear, delivering results within a week of sample receipt along with neurologist-guided next steps.

Differentiator

Problem solved

Functional benefit

Products and services

• Neurogen At-Home Alzheimer's Test Kit A direct-to-consumer at-home Alzheimer's test kit enabling early detection of Alzheimer's disease risk up to 10 years before symptoms appear. Includes at-home blood collection via phlebotomy or Tasso needle-free device, digital cognitive assessments, board-certified neurologist review, telehealth consultation, and a personalized brain health action plan.
• P-tau217 Blood Biomarker Test A blood test measuring phosphorylated tau 217 (P-tau217) protein levels, a specific biomarker for Alzheimer's disease pathology and Mild Cognitive Impairment. Uses Quanterix's ultrasensitive Simoa technology for high-accuracy detection (near 96% accuracy for elevated p-tau217) from a simple blood draw.
• Digital Cognitive Assessment AI-powered online cognitive assessments administered in partnership with Linus Health that evaluate memory, thinking, and cognitive abilities to identify early signs of cognitive impairment alongside blood biomarker results.
• Telehealth Neurologist Consultation Board-certified neurologists (via the NeuroX telehealth platform) review blood test and cognitive assessment results and provide telehealth appointments to explain findings in plain language and advise on personalized next steps for care. The initial consultation is included with kit purchase.
• Personalized Brain Health Action Plan A customized brain health roadmap provided after testing, including lifestyle recommendations (exercise, diet, sleep), ongoing monitoring guidance, and clear action steps tailored to the individual's biomarker and cognitive assessment results.
• Secure Patient Portal and Lifetime Results Tracking A secure patient portal enabling tracking of test kits, viewing of results, secure communication with neurologists, and ongoing brain health monitoring over time through the Neurogen platform.

Quantifiable outcome

• Diagnostic timeline reduced from years to months through at-home testing platform
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability5 records

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• TassocoreTechnology or Integration · 20 November 2025Neurogen partnered with Tasso to incorporate needle-free blood collection technology into its Alzheimer's testing platform. The collaboration aims to improve accessibility to at-home biomarker testing by enabling virtually painless blood sample collection without requiring nurse or needle. Tasso's FDA-cleared device allows self-administered sample collection, improving patient convenience and expanding access to early Alzheimer's diagnosis.
• Global Alzheimer's Platform FoundationminorGTM or Marketing Partner · 10 May 2025Non-profit organization co-sponsoring community Brain Health Day events to address urgent need for early Alzheimer's detection, particularly among underserved populations most affected by the disease.
• Insight HospitalminorImplementation/ SI/ Consulting Partner · 10 May 2025Chicago hospital hosting Neurogen's Brain Health Day community event, providing venue and co-promotion of early Alzheimer's detection services to local community.
• NeuroXcoreTechnology or Integration · 1 May 2025Partnership with NeuroX (subsidiary of American TelePhysicians) provides virtual neurology services through board-certified neurologists with specialized training in early Alzheimer's detection. NeuroX neurologists guide patients through the Neurogen journey including blood biomarker results interpretation, personalized brain health reports, and action plans. AI-powered virtual care ecosystem delivers cognitive care in weeks rather than the 45-50 months typical of traditional neurology referrals.
• QuanterixcoreTechnology or Integration · 19 February 2025Exclusive global agreement giving Neurogen rights to use Quanterix's ultrasensitive antibody technology to measure p-tau217 blood biomarker for early detection of dementia and Mild Cognitive Impairment due to Alzheimer's disease. The agreement covers commercial rights in US, Europe, and pan-Asia for direct-to-consumer testing. Quanterix's technology enables testing for AD pathology in blood that was previously only possible through invasive procedures.
• Linus HealthcoreTechnology or Integration · 14 January 2025Collaboration integrates Linus Health's scientifically-validated digital cognitive assessments into the Neurogen ecosystem. Linus Health develops AI-powered online cognitive assessments that combine long-trusted cognitive tests with advanced technology to detect signs of cognitive impairment in early stages. The assessments identify high-risk individuals and determine eligibility for further evaluation within the Neurogen platform.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Altoida: FDA Breakthrough-designated digital SaMD that uses smartphone-based cognitive testing and AR tasks to predict Alzheimer's risk — overlaps Neurogen in the digital cognitive-assessment layer of the AD detection stack.
• BrainCheck: Digital cognitive assessment platform used by clinicians and health systems to detect and manage cognitive impairment — overlaps with Neurogen's Linus Health integration and serves a similar early-detection use case.
• Linus Health: AI-powered digital cognitive assessment platform for early detection of cognitive impairment — directly integrated as Neurogen's cognitive assessment partner, and a potential standalone competitor in the digital brain-health category.
• Neurotrack: Digital cognitive assessment and brain-health program focused on early memory decline detection — comparable to Neurogen's cognitive-assessment-and-care-plan offering for at-risk consumers.

Broad incumbents

• Quest Diagnostics: Major clinical reference lab offering AD-related biomarker tests (including p-tau217 via the LucentAD p-tau217 assay and AD-Detect) with national phlebotomy infrastructure and insurance billing — represents the scaled, reimbursed alternative to Neurogen's DTC model.
• Biogen: Developer of Leqembi, an FDA-approved anti-amyloid Alzheimer's therapy that requires confirmed amyloid pathology for eligibility — a key therapeutic tailwind for early-detection platforms like Neurogen and an indirect competitor shaping the AD care continuum.
• Labcorp: Large national clinical laboratory with established AD biomarker testing capabilities and broad payer coverage — comparable to Quest as a potential scaled competitor that could match Neurogen's testing functionality within existing clinical workflows.

Others

• Quanterix: Technology partner and licensor of the Simoa p-tau217 antibody platform that underpins Neurogen's test — also a direct-to-research/reagent provider to other AD biomarker developers and a potential upstream competitor or acquirer.
• American TelePhysicians (NeuroX): Parent of NeuroX, Neurogen's telehealth neurology partner; provides the virtual neurology network underpinning Neurogen's consultation layer and the CMS GUIDE Model connection.

Direct peers

• C2N Diagnostics: Direct-to-consumer and clinician-facing blood-based Alzheimer's biomarker test (PrecivityAD) using mass spectrometry to measure Aβ42/40 ratio — the most established DTC blood-biomarker AD test and the closest head-to-head competitor to Neurogen.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/neurogen-biomarking
• Facebookfacebook.com/NeurogenBiomarking

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neurogen Biomarking